CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 24 enrolled
Drug / intervention
somatropindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02726542
NCT02726542Early Ph 1Completed
CompareCT.gov

Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents

Massachusetts General Hospital·interventional·Posted Apr 1, 2016·Updated Sep 7, 2022

In Brief

A Early Phase 1 clinical trial evaluating somatropin for NAFLD. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Fatty liver disease is an increasing problem in overweight and obese young adults. The purpose of this study is to test the effect of growth hormone on liver fat in obese young adults ages 18-29y with increased liver fat.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNAFLD
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 1, 2016
Enrollment StartMay 3, 2017
Primary CompletionApr 2, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.3 years ago

Interventions

somatropindrug

Norditropin (growth hormone) given by injection using a pen-device